Detalles de la búsqueda
1.
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.
Br J Cancer
; 129(5): 811-818, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37488446
2.
Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer.
Invest New Drugs
; 39(1): 193-201, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32915419
3.
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations.
Invest New Drugs
; 39(5): 1324-1334, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33774767
4.
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
Invest New Drugs
; 39(4): 1089-1098, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33686452
5.
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts.
Cancer Sci
; 111(2): 536-547, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31778267
6.
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.
J Neurooncol
; 146(1): 79-89, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31776899
7.
Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.
Invest New Drugs
; 36(3): 476-486, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29177975
8.
A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.
Invest New Drugs
; 33(3): 710-9, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25902900
9.
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-ß receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
Invest New Drugs
; 33(2): 357-70, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25529192
10.
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors.
Sci Transl Med
; 15(695): eabp9229, 2023 05 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37163618
11.
High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer.
Clin Cancer Res
; 28(1): 137-149, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34593528
12.
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Nat Commun
; 13(1): 5258, 2022 09 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36071033
13.
Gastrointestinal safety of triflusal solution in healthy volunteers: a proof of concept endoscopic study.
Eur J Clin Pharmacol
; 67(7): 663-9, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21327422
14.
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
J Clin Oncol
; 39(2): 145-154, 2021 01 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33301375
15.
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials.
Eur J Cancer
; 155: 168-178, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34385069
16.
Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours.
ESMO Open
; 5(6): e001081, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33262202
17.
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Clin Cancer Res
; 26(8): 1846-1855, 2020 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31757877
18.
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication.
Ther Adv Med Oncol
; 11: 1758835919833867, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31205497
19.
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.
Oncotarget
; 9(60): 31709-31718, 2018 Aug 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30167089
20.
Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours.
Eur J Cancer
; 103: 88-97, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30218977